{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:17:58Z","timestamp":1782789478967,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102499","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:15:26Z","timestamp":1767629726000},"page":"102499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 (177Lu)\u2013PSMA-617: A Retrospective Real-World Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Mohammad Hadi","family":"Samadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Shamshirgaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8772-2502","authenticated-orcid":false,"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-6242","authenticated-orcid":false,"given":"Haniye","family":"Elahifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-8236","authenticated-orcid":false,"given":"Ghasemali","family":"Divband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102499_bib0001","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10459","key":"10.1016\/j.clgc.2025.102499_bib0002","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clgc.2025.102499_bib0003","first-page":"e546","article-title":"PSMAddition: phase 3 trial of [177lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.clgc.2025.102499_bib0004","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102499_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2025.102499_bib0007","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102499_bib0008","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.clgc.2025.102499_bib0010","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10276","key":"10.1016\/j.clgc.2025.102499_bib0011","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clgc.2025.102499_bib0012","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [<sup>177<sup>Lu]Lu-PSMA: a German multicenter study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102499_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0014","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"10.1016\/j.clgc.2025.102499_bib0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00432-017-2577-1","article-title":"Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study","volume":"144","author":"Honecker","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102499_bib0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0000000000001087","article-title":"Risk factors for early treatment discontinuation due to toxicity among patients with metastatic castration-resistant prostate cancer receiving androgen receptor-targeted therapy","volume":"47","author":"Chakrani","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102499_bib0017","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.clgc.2025.102499_bib0018","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clgc.2025.102499_bib0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102499_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0021","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12094-018-1940-2","article-title":"Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology","volume":"21","author":"G\u00f3mez-Caama\u00f1o","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102499_bib0022","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1097\/RLU.0000000000005445","article-title":"Tumor lysis syndrome following PSMA radioligand therapy","volume":"49","author":"Sahafi","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.gpb.2016.03.006","article-title":"Comparison of cox model methods in a low-dimensional setting with few events","volume":"14","author":"Ojeda","year":"2016","journal-title":"Geno Proteom Bioinform"},{"issue":"7","key":"10.1016\/j.clgc.2025.102499_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0025","first-page":"239","article-title":"Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with (177)Lu-PSMA-617: a single center study","volume":"41","author":"Zarehparvar Moghadam","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"10.1016\/j.clgc.2025.102499_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01034-y","article-title":"Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","author":"Yanagisawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.clgc.2025.102499_bib0027","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [(177)Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. Expanded-Access program and comparisons with phase 3 VISION data","volume":"65","author":"Murthy","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102499_bib0028","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102499_bib0029","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","article-title":"Initial experience with [(177)Lu]Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clgc.2025.102499_bib0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102499_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2967\/jnumed.124.268902","article-title":"(177)Lu-DOTATATE in combination with PARP inhibitor olaparib is feasible in patients with somatostatin-positive tumors: results from the LuPARP Phase I trial","volume":"66","author":"Hallqvist","year":"2025","journal-title":"J Nucl Med"},{"issue":"10276","key":"10.1016\/j.clgc.2025.102499_bib0032","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.clgc.2025.102499_bib0033","doi-asserted-by":"crossref","DOI":"10.1007\/s12149-025-02127-3","article-title":"Efficacy and safety of lutetium-177 (177Lu)-PSMA-617 in metastatic castration-resistant prostate cancer patients with superscan pattern: a retrospective cohort study","author":"Shamshirgaran","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102499_bib0034","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13550-025-01312-9","article-title":"AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis","volume":"15","author":"Ruhwedel","year":"2025","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.clgc.2025.102499_bib0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","article-title":"Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer","volume":"46","author":"Yordanova","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.clgc.2025.102499_bib0036","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102499_bib0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:29:20Z","timestamp":1771705760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767325001995"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102499","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 (177Lu)\u2013PSMA-617: A Retrospective Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102499"}}